B. Engelhardt and R. Ransohoff, The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms, Trends in Immunology, vol.26, issue.9, pp.485-495, 2005.
DOI : 10.1016/j.it.2005.07.004

J. Greenwood, S. Heasman, J. Alvarez, A. Prat, R. Lyck et al., Review: Leucocyte-endothelial cell crosstalk at the blood-brain barrier: A prerequisite for successful immune cell entry to the brain, Neuropathology and Applied Neurobiology, vol.25, issue.1, pp.24-39, 2011.
DOI : 10.1111/j.1365-2990.2010.01140.x

M. Ukkonen, K. Wu, B. Reipert, P. Dastidar, and I. Elovaara, Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis, Multiple Sclerosis, vol.13, issue.6, pp.701-707, 2007.
DOI : 10.1177/1352458506075378

C. Brosnan, B. Cannella, L. Battistini, and C. Raine, Cytokine localization in multiple sclerosis lesions: Correlation with adhesion molecule expression and reactive nitrogen species, Neurology, vol.45, issue.Issue 6, Supplement 6, pp.16-21, 1995.
DOI : 10.1212/WNL.45.6_Suppl_6.S16

T. Yednock, C. Cannon, L. Fritz, F. Sanchez-madrid, L. Steinman et al., Prevention of experimental autoimmune encephalomyelitis by antibodies against ??4??l integrin, Nature, vol.356, issue.6364, pp.63-66, 1992.
DOI : 10.1038/356063a0

C. Polman, O. Connor, P. Havrdova, E. Hutchinson, M. Kappos et al., A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.354, issue.9, pp.899-910, 2006.
DOI : 10.1056/NEJMoa044397

A. Millonig, H. Hegen, D. Pauli, F. Ehling, R. Gneiss et al., Natalizumab treatment reduces endothelial activity in MS patients, Journal of Neuroimmunology, vol.227, issue.1-2, pp.190-194, 2010.
DOI : 10.1016/j.jneuroim.2010.07.012

H. Lipton, D. Canto, and M. , Chronic neurologic disease in Theiler's virus infection of SJL/J mice, Journal of the Neurological Sciences, vol.30, issue.1, pp.201-207, 1976.
DOI : 10.1016/0022-510X(76)90267-7

M. Maccarrone, E. Dainese, and S. Oddi, Intracellular trafficking of anandamide: new concepts for signaling, Trends in Biochemical Sciences, vol.35, issue.11, pp.601-608, 2010.
DOI : 10.1016/j.tibs.2010.05.008

E. Scotter, M. Abood, and M. Glass, The endocannabinoid system as a target for the treatment of neurodegenerative disease, British Journal of Pharmacology, vol.400, issue.3, pp.480-498, 2010.
DOI : 10.1111/j.1476-5381.2010.00735.x

S. Rossi, G. Bernardi, and D. Centonze, The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis, Experimental Neurology, vol.224, issue.1, pp.92-102, 2010.
DOI : 10.1016/j.expneurol.2010.03.030

G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder et al., CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity, Science, vol.302, issue.5642, pp.84-88, 2003.
DOI : 10.1126/science.1088208

URL : http://hdl.handle.net/11858/00-001M-0000-000E-9E00-4

E. Eljaschewitsch, A. Witting, C. Mawrin, T. Lee, P. Schmidt et al., The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells, Neuron, vol.49, issue.1, pp.67-79, 2006.
DOI : 10.1016/j.neuron.2005.11.027

D. Panikashvili, N. Shein, R. Mechoulam, V. Trembovler, R. Kohen et al., The endocannabinoid 2-AG protects the blood???brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines, Neurobiology of Disease, vol.22, issue.2, pp.257-264, 2006.
DOI : 10.1016/j.nbd.2005.11.004

D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan et al., The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis, Brain, vol.130, issue.10, pp.2543-2553, 2007.
DOI : 10.1093/brain/awm160

C. Fowler, M. Rojo, and . Rodriguez-gaztelumendi, Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?, Experimental Neurology, vol.224, issue.1, pp.37-47, 2010.
DOI : 10.1016/j.expneurol.2010.03.021

A. Cabranes, K. Venderova, E. De-lago, F. Fezza, A. Sánchez et al., Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis, Neurobiology of Disease, vol.20, issue.2, pp.207-217, 2005.
DOI : 10.1016/j.nbd.2005.03.002

S. Ortega-gutiérrez, E. Molina-holgado, A. Arévalo-martín, F. Correa, A. Viso et al., Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis, The FASEB Journal, vol.19, pp.1338-1340, 2005.
DOI : 10.1096/fj.04-2464fje

D. Centonze, L. Battistini, and M. Maccarrone, The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases, Current Pharmaceutical Design, vol.14, issue.23, pp.2370-2342, 2008.
DOI : 10.2174/138161208785740018

D. Baker, P. G. Croxford, J. Brown, P. Pertwee, R. Makriyannis et al., Endocannabinoids control spasticity in a multiple sclerosis model, The FASEB Journal, vol.15, pp.300-302, 2001.
DOI : 10.1096/fj.00-0399fje

A. Arévalo-martín, J. Vela, E. Molina-holgado, J. Borrell, and C. Guaza, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, J Neurosci, vol.23, pp.2511-2516, 2003.

J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery et al., Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, The Lancet, vol.362, issue.9395, pp.1517-1526, 2003.
DOI : 10.1016/S0140-6736(03)14738-1

X. Ni, E. Geller, M. Eppihimer, T. Eisenstein, M. Adler et al., Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/ endothelial interactions in an experimental autoimmune encephalomyelitis model, Multiple Sclerosis, vol.10, issue.2, pp.158-164, 2004.
DOI : 10.1191/1352458504ms1009oa

L. Mestre, F. Docagne, F. Correa, F. Loría, M. Hernangómez et al., A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules, Molecular and Cellular Neuroscience, vol.40, issue.2, pp.258-266, 2009.
DOI : 10.1016/j.mcn.2008.10.015

A. Lledó, J. Borrell, and C. Guaza, Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination, European Journal of Pharmacology, vol.372, issue.1, pp.75-83, 1999.
DOI : 10.1016/S0014-2999(99)00187-9

M. Laschinger and B. Engelhardt, Interaction of ??4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro, Journal of Neuroimmunology, vol.102, issue.1, pp.32-43, 2000.
DOI : 10.1016/S0165-5728(99)00156-3

Y. Omidi, L. Campbell, J. Barar, D. Connell, S. Akhtar et al., Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood???brain barrier model for drug uptake and transport studies, Brain Research, vol.990, issue.1-2, pp.95-112, 2003.
DOI : 10.1016/S0006-8993(03)03443-7

T. Yang, K. Roder, and T. Abbruscato, Evaluation of bEnd5 cell line as an in vitro model for the blood???brain barrier under normal and hypoxic/aglycemic conditions, Journal of Pharmaceutical Sciences, vol.96, issue.12, pp.3196-3213, 2007.
DOI : 10.1002/jps.21002

F. Molina-holgado, A. Lledó, and C. Guaza, Evidence for cyclooxygenase activation by nitric oxide in astrocytes, Glia, vol.247, issue.2, pp.167-172, 1995.
DOI : 10.1002/glia.440150209

P. Gaillard, L. Voorwinden, J. Nielsen, A. Ivanov, R. Atsumi et al., Establishment and functional characterization of an in vitro model of the blood???brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes, European Journal of Pharmaceutical Sciences, vol.12, issue.3, pp.215-222, 2001.
DOI : 10.1016/S0928-0987(00)00123-8

E. Eugenin and J. Berman, Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood???brain barrier, Methods, vol.29, issue.4, pp.351-361, 2003.
DOI : 10.1016/S1046-2023(02)00359-6

S. Golech, R. Mccarron, Y. Chen, J. Bembry, F. Lenz et al., Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors, Molecular Brain Research, vol.132, issue.1, pp.87-92, 2004.
DOI : 10.1016/j.molbrainres.2004.08.025

O. Sullivan and S. , Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors, British Journal of Pharmacology, vol.100, issue.5, pp.576-582, 2007.
DOI : 10.1038/sj.bjp.0707423

S. Wolf, S. Tauber, and O. Ullrich, CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control, Current Pharmaceutical Design, vol.14, issue.23, pp.2266-2278, 2008.
DOI : 10.2174/138161208785740090

URL : http://doi.org/10.2174/138161208785740090

E. Molina-holgado and F. Molina-holgado, Mending the broken brain: neuroimmune interactions in neurogenesis, Journal of Neurochemistry, vol.9, issue.Suppl 1, pp.1277-1290, 2010.
DOI : 10.1111/j.1471-4159.2010.06849.x

R. Pertwee, Emerging strategies for exploiting cannabinoid receptor agonists as medicines, British Journal of Pharmacology, vol.152, issue.2, pp.397-411, 2009.
DOI : 10.1111/j.1476-5381.2008.00048.x

J. Croxford, P. G. Jackson, S. Ledent, C. Giovannoni, G. Pertwee et al., Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis, Journal of Neuroimmunology, vol.193, issue.1-2, pp.120-129, 2008.
DOI : 10.1016/j.jneuroim.2007.10.024

B. Sapatino, A. Petrescu, B. Rosenbaum, R. Smith, J. Piedrahita et al., Characteristics of cloned cerebrovascular endothelial cells following infection with Theiler's virus II. Persistent infection, Journal of Neuroimmunology, vol.62, issue.2, pp.127-135, 1995.
DOI : 10.1016/0165-5728(95)00094-4

A. Inoue, C. Koh, M. Yamazaki, M. Ichikawa, M. Isobe et al., Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease, International Immunology, vol.9, issue.12, pp.1837-1847, 1997.
DOI : 10.1093/intimm/9.12.1837

L. Mestre, F. Correa, F. Docagne, D. Clemente, and C. Guaza, The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection, Biochemical Pharmacology, vol.72, issue.7, pp.869-880, 2006.
DOI : 10.1016/j.bcp.2006.06.037

M. Maccarrone, A. Fiori, M. Bari, F. Granata, V. Gasperi et al., Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells, Thrombosis and Haemostasis, vol.95, pp.117-127, 2006.
DOI : 10.1160/TH05-06-0413

T. Lu, H. Avraham, S. Seng, S. Tachado, H. Koziel et al., Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells, The Journal of Immunology, vol.181, issue.9, pp.6406-6416, 2008.
DOI : 10.4049/jimmunol.181.9.6406

H. Zhang, D. Hilton, C. Hanemann, and J. Zajicek, Cannabinoid Receptor and N-acyl Phosphatidylethanolamine Phospholipase D-Evidence for Altered Expression in Multiple Sclerosis, Brain Pathology, vol.4, 2011.
DOI : 10.1111/j.1750-3639.2011.00477.x

C. Benito, J. Romero, R. Tolón, D. Clemente, F. Docagne et al., Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis, Journal of Neuroscience, vol.27, issue.9, pp.2396-402, 2007.
DOI : 10.1523/JNEUROSCI.4814-06.2007

Y. Yiangou, P. Facer, P. Durrenberger, I. Chessell, A. Naylor et al., COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurology, vol.3, issue.1, p.12, 2006.
DOI : 10.1016/S1471-4892(02)00004-8

S. Ramirez, D. Heilman, B. Morsey, R. Potula, J. Haorah et al., Activation of Peroxisome Proliferator-Activated Receptor ?? (PPAR??) Suppresses Rho GTPases in Human Brain Microvascular Endothelial Cells and Inhibits Adhesion and Transendothelial Migration of HIV-1 Infected Monocytes, The Journal of Immunology, vol.180, issue.3, pp.1854-1865, 2008.
DOI : 10.4049/jimmunol.180.3.1854

L. Craig, J. Spelman, J. Strandberg, and M. Zink, Endothelial Cells from Diverse Tissues Exhibit Differences in Growth and Morphology, Microvascular Research, vol.55, issue.1, pp.65-76, 1998.
DOI : 10.1006/mvre.1997.2045

P. Chen, S. Hu, J. Yao, S. Moore, and A. Spector, Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium, Microvascular Research, vol.69, issue.1-2, pp.28-35, 2005.
DOI : 10.1016/j.mvr.2005.02.001

F. Loría, S. Petrosino, L. Mestre, A. Spagnolo, F. Correa et al., Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a

. Mestre, http://www.jneuroinflammation.com/content/8/1/102 therapeutic effect of palmitoylethanolamide, Journal of Neuroinflammation Eur J Neurosci, vol.8, issue.28, pp.102633-641, 2008.

L. Mestre, F. Correa, A. Arévalo-martín, E. Molina-holgado, M. Valenti et al., Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis, Journal of Neurochemistry, vol.118, issue.6
DOI : 10.1111/j.1471-4159.2004.02979.x

J. Wagner, K. Hu, J. Karcher, J. Bauersachs, A. Schäfer et al., cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction, British Journal of Pharmacology, vol.400, issue.7, pp.1251-1258, 2003.
DOI : 10.1038/sj.bjp.0705156

N. Battista, F. Fezza, and M. Maccarrone, Endocannabinoids and their Involvement in the Neurovascular System, Current Neurovascular Research, vol.1, issue.2, pp.129-140, 2004.
DOI : 10.2174/1567202043480107

L. Walter and N. Stella, Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes, Glia, vol.23, issue.1, pp.85-90, 2003.
DOI : 10.1002/glia.10270

N. Stella, Endocannabinoid signaling in microglial cells, Neuropharmacology, vol.56, pp.244-253, 2009.
DOI : 10.1016/j.neuropharm.2008.07.037

R. Mechoulam and E. Shohami, Endocannabinoids and Traumatic Brain Injury, Molecular Neurobiology, vol.6, issue.suppl 11, pp.68-74, 2007.
DOI : 10.1007/s12035-007-8008-6

O. Ullrich, K. Merker, J. Timm, and S. Tauber, Immune control by endocannabinoids ??? New mechanisms of neuroprotection?, Journal of Neuroimmunology, vol.184, issue.1-2, pp.127-135, 2007.
DOI : 10.1016/j.jneuroim.2006.11.018

J. Olson and S. Miller, The Innate Immune Response Affects the Development of the Autoimmune Response in Theiler's Virus-Induced Demyelinating Disease, The Journal of Immunology, vol.182, issue.9, pp.5712-5722, 2009.
DOI : 10.4049/jimmunol.0801940

F. Molina-holgado, E. Molina-holgado, and C. Guaza, The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway, FEBS Letters, vol.23, issue.1-2, pp.139-142, 1998.
DOI : 10.1016/S0014-5793(98)00851-5

F. Correa, M. Hernangómez-herrero, L. Mestre, F. Loría, F. Docagne et al., The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells, Brain, Behavior, and Immunity, vol.25, issue.4, pp.736-749, 2011.
DOI : 10.1016/j.bbi.2011.01.020

Y. Jin, M. Mohindru, M. Kang, A. Fuller, B. Kang et al., Differential Virus Replication, Cytokine Production, and Antigen-Presenting Function by Microglia from Susceptible and Resistant Mice Infected with Theiler's Virus, Journal of Virology, vol.81, issue.21, pp.11690-11702, 2007.
DOI : 10.1128/JVI.01034-07

G. Pryce, Z. Ahmed, D. Hankey, S. Jackson, J. Croxford et al., Cannabinoids inhibit neurodegeneration in models of multiple sclerosis, Brain, vol.126, issue.10, pp.2191-2202, 2003.
DOI : 10.1093/brain/awg224

S. Jackson, P. G. Diemel, L. Cuzner, M. Baker, and D. , Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation, Neuroscience, vol.134, issue.1, pp.261-268, 2005.
DOI : 10.1016/j.neuroscience.2005.02.045

E. Ramil, A. Sánchez, P. González-pérez, A. Rodríguez-antigüedad, N. Gómez-lozano et al., The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain, Multiple Sclerosis Journal, vol.14, issue.1, pp.139-146, 2010.
DOI : 10.2307/2532296

S. Rossi, F. Buttari, V. Studer, C. Motta, P. Gravina et al., receptor gene influences disease progression in relapsing multiple sclerosis, Multiple Sclerosis Journal, vol.95, issue.3, pp.281-288, 2011.
DOI : 10.1093/brain/awq076